{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:04:29Z","timestamp":1784127869944,"version":"3.55.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["15\/576"],"award-info":[{"award-number":["15\/576"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007288","name":"Mahasarakham University","doi-asserted-by":"publisher","award":["31,32,34,60,72"],"award-info":[{"award-number":["31,32,34,60,72"]}],"id":[{"id":"10.13039\/501100007288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007288","name":"Mahasarakham University","doi-asserted-by":"publisher","award":["6,7,9"],"award-info":[{"award-number":["6,7,9"]}],"id":[{"id":"10.13039\/501100007288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.berh.2019.03.010","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T17:36:23Z","timestamp":1555090583000},"page":"813-834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Management of complex gout in clinical practice: Update on therapeutic approaches"],"prefix":"10.1016","volume":"32","author":[{"given":"Ravi K.","family":"Narang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.berh.2019.03.010_bib1","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.03.010_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-10-117","article-title":"Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey","volume":"10","author":"Khanna","year":"2012","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"10.1016\/j.berh.2019.03.010_bib3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/ncprheum0556","article-title":"The changing epidemiology of gout","volume":"3","author":"Roddy","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.berh.2019.03.010_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2474-12-103","article-title":"Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population","volume":"12","author":"Primatesta","year":"2011","journal-title":"BMC Muscoskelet Disord"},{"issue":"10","key":"10.1016\/j.berh.2019.03.010_bib5","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.168.10.1104","article-title":"Long-term cardiovascular mortality among middle-aged men with gout","volume":"168","author":"Krishnan","year":"2008","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.berh.2019.03.010_bib6","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/rheumatology\/kex150","article-title":"The British society for rheumatology guideline for the management of gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.berh.2019.03.010_bib7","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"10.1016\/j.berh.2019.03.010_bib8","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.berh.2019.03.010_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2019.03.010_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2019.03.010_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.140458","article-title":"The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors","volume":"92","author":"Wechalekar","year":"2014","journal-title":"J\u00a0Rheumatol Suppl"},{"key":"10.1016\/j.berh.2019.03.010_bib12","first-page":"810","article-title":"Comparison of prednisolone, etoricoxib, and indomethacin in treatment of acute gouty arthritis: an open-label, randomized, controlled trial","volume":"22","author":"Xu","year":"2016","journal-title":"Med Sci Mon Int Med J Exp Clin Res"},{"issue":"7","key":"10.1016\/j.berh.2019.03.010_bib13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/M14-2070","article-title":"Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial","volume":"164","author":"Rainer","year":"2016","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.berh.2019.03.010_bib14","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2019.03.010_bib15","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.30389","article-title":"Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/P-glycoprotein inhibitors","volume":"63","author":"Terkeltaub","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"7081","key":"10.1016\/j.berh.2019.03.010_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.berh.2019.03.010_bib17","unstructured":"Agency EM. European public assessment report: Ilaris 10 May 2013. Contract No.: (EMEA\/H\/C\/001109\/II\/0010)."},{"key":"10.1016\/j.berh.2019.03.010_bib18","series-title":"Ilaris (canakinumab)-Summary minutes and transcript of the arthritis advisory committee meeting","author":"Administration FaD","year":"2011"},{"issue":"11","key":"10.1016\/j.berh.2019.03.010_bib19","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2019.03.010_bib20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.7326\/M18-1167","article-title":"Relationship of interleukin-1beta blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial","volume":"169","author":"Solomon","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.berh.2019.03.010_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0009-9236(03)00094-8","article-title":"Pharmacokinetics of anakinra in subjects with different levels of renal function","volume":"74","author":"Yang","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.berh.2019.03.010_bib22","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A\u00a0pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.berh.2019.03.010_bib23","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/acr.21989","article-title":"Treatment of acute gouty arthritis in complex hospitalized patients with anakinra","volume":"65","author":"Ghosh","year":"2013","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.berh.2019.03.010_bib24","unstructured":"Excellence NIfHaC. Final appraisal determination \u2013 Anakinra for rheumatoid arthritis United Kingdom: NICE; [cited July 2003]."},{"key":"10.1016\/j.berh.2019.03.010_bib25","unstructured":"Excellence NIfHaC. Gouty arthritis: canakinumab United Kingdom: NICE; Evidence summary [ESNM23]; [cited July 2013]."},{"issue":"9","key":"10.1016\/j.berh.2019.03.010_bib26","doi-asserted-by":"crossref","first-page":"617","DOI":"10.7326\/M14-0227","article-title":"Cost-effectiveness of allopurinol and febuxostat for the management of gout","volume":"161","author":"Jutkowitz","year":"2014","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.berh.2019.03.010_bib27","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2019.03.010_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity - description and guidelines for prevention in patients with renal-insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.berh.2019.03.010_bib29","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","article-title":"An open-label, 6-month study of allopurinol safety in gout: the LASSO study","volume":"45","author":"Becker","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2019.03.010_bib30","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2019.03.010_bib31","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A\u00a0randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2019.03.010_bib32","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","article-title":"Allopurinol dose escalation to achieve serum urate below 6 mg\/dL: an open-label extension study","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.03.010_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1491-x","article-title":"The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial","volume":"19","author":"Stamp","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.berh.2019.03.010_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.berh.2019.03.010_bib35","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2019.03.010_bib36","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.berh.2019.03.010_bib37","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenetics Genom"},{"key":"10.1016\/j.berh.2019.03.010_bib38","first-page":"351","article-title":"Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study","author":"Ko","year":"2015","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.berh.2019.03.010_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094294","article-title":"Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS\/TEN in Thai population","volume":"9","author":"Saokaew","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.berh.2019.03.010_bib40","first-page":"983","article-title":"Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis","volume":"20","author":"Borghi","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.berh.2019.03.010_bib41","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.berh.2019.03.010_bib42","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"13","key":"10.1016\/j.berh.2019.03.010_bib43","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2019.03.010_bib44","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/jcpt.12391","article-title":"Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study","volume":"41","author":"Hosoya","year":"2016","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"3","key":"10.1016\/j.berh.2019.03.010_bib45","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0168-8278(94)80011-1","article-title":"Hepatic-injury caused by benzbromarone","volume":"20","author":"Vanderklauw","year":"1994","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.berh.2019.03.010_bib46","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1046\/j.1440-1746.2002.02692.x","article-title":"Fulminant hepatic failure associated with benzbromarone treatment: a case report","volume":"17","author":"Arai","year":"2002","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.berh.2019.03.010_bib47","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","article-title":"Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients","volume":"26","author":"Reinders","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2019.03.010_bib48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2019.03.010_bib49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2019.03.010_bib50","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2019.03.010_bib51","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2019.03.010_bib52","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study","volume":"56","author":"Tausche","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.berh.2019.03.010_bib53","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jama.2017.20189","article-title":"Lesinurad\/allopurinol (Duzallo) for gout-associated hyperuricemia","volume":"319","author":"Abramowicz","year":"2018","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.berh.2019.03.010_bib54","first-page":"S697","article-title":"Arhalofenate is a novel dual-acting agent with uricosuric and anti-inflammatory properties","volume":"64","author":"Choi","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2019.03.010_bib55","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/art.39684","article-title":"A\u00a0randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout","volume":"68","author":"Poiley","year":"2016","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2019.03.010_bib56","article-title":"Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study","volume":"4","author":"Fleischmann","year":"2018","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.berh.2019.03.010_bib57","article-title":"Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study","volume":"4","author":"Fleischmann","year":"2018","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.berh.2019.03.010_bib58","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/rheumatology\/key100","article-title":"Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study","volume":"57","author":"Shiramoto","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2019.03.010_bib59","first-page":"1","article-title":"Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and\/or asymptomatic hyperuricemia in the United States and Japan: findings from two Phase II trials","author":"Fitz-Patrick","year":"2018","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2019.03.010_bib60","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/ar4318","article-title":"Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy","volume":"15","author":"Baraf","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.berh.2019.03.010_bib61","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3899\/jrheum.111375","article-title":"Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials","volume":"39","author":"Strand","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2019.03.010_bib62","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.berh.2019.03.010_bib63","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1136\/annrheumdis-2012-201795","article-title":"Long-term safety of pegloticase in chronic gout refractory to conventional treatment","volume":"72","author":"Becker","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.03.010_bib64","series-title":"KRYSTEXXA (Pegloticase) - highlights of prescribing information food and drug administration","author":"Pharmaceuticals","year":"2012"},{"issue":"5","key":"10.1016\/j.berh.2019.03.010_bib65","first-page":"908","article-title":"A\u00a0cost-effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty-arthritis","volume":"22","author":"Ferraz","year":"1995","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2019.03.010_bib66","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/art.40233","article-title":"Effects of febuxostat in early gout a randomized, double-blind, placebo-controlled study","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2019.03.010_bib67","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.amjmed.2012.05.025","article-title":"Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial","volume":"125","author":"Taylor","year":"2012","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.berh.2019.03.010_bib68","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/RHU.0000000000000235","article-title":"Does starting allopurinol prolong acute treated gout? A randomized clinical trial","volume":"21","author":"Hill","year":"2015","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2019.03.010_bib69","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/art.1780150209","article-title":"The influence of temperature on the solubility of monosodium urate","volume":"15","author":"Loeb","year":"1972","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2019.03.010_bib70","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2019.03.010_bib71","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A\u00a0retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"23","key":"10.1016\/j.berh.2019.03.010_bib72","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.berh.2019.03.010_bib73","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.30649","article-title":"A\u00a0two-stage approach to the treatment of hyperuricemia in gout: the \"Dirty Dish\" hypothesis","volume":"63","author":"Perez-Ruiz","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2019.03.010_bib74","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J\u00a0Rheumatol"},{"issue":"14","key":"10.1016\/j.berh.2019.03.010_bib75","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","article-title":"Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials","volume":"32","author":"Wortmann","year":"2010","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.berh.2019.03.010_bib76","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study","volume":"77","author":"Yamanaka","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2019.03.010_bib77","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0895-4356(88)90127-8","article-title":"Gout and coronary heart-disease - the framingham-study","volume":"41","author":"Abbott","year":"1988","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.berh.2019.03.010_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000282","article-title":"Gout and the risk for incident heart failure and systolic dysfunction","volume":"2","author":"Krishnan","year":"2012","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.berh.2019.03.010_bib79","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-011-0234-2","article-title":"Association between gout and all-cause as well as cardiovascular mortality: a systematic review","volume":"14","author":"Lottmann","year":"2012","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.berh.2019.03.010_bib80","doi-asserted-by":"crossref","first-page":"653 e7","DOI":"10.1016\/j.amjmed.2015.01.013","article-title":"Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study","volume":"128","author":"Kim","year":"2015","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.berh.2019.03.010_bib81","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/HYPERTENSIONAHA.115.06344","article-title":"Allopurinol and cardiovascular outcomes in adults with hypertension","volume":"67","author":"MacIsaac","year":"2016","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.berh.2019.03.010_bib82","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/rheumatology\/kex065","article-title":"Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis","volume":"56","author":"Zhang","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.berh.2019.03.010_bib83","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.berh.2019.03.010_bib84","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.berh.2019.03.010_bib85","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1136\/annrheumdis-2015-207984","article-title":"Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims","volume":"75","author":"Solomon","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2019.03.010_bib86","first-page":"CD010039","article-title":"Lifestyle interventions for chronic gout","author":"Moi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.berh.2019.03.010_bib87","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1136\/annrheumdis-2017-211472","article-title":"Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies","volume":"76","author":"Nielsen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2019.03.010_bib88","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, dairy and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"7639","key":"10.1016\/j.berh.2019.03.010_bib89","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.39449.819271.BE","article-title":"Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study","volume":"336","author":"Choi","year":"2008","journal-title":"BMJ"},{"issue":"9417","key":"10.1016\/j.berh.2019.03.010_bib90","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: a prospective study","volume":"363","author":"Choi","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.berh.2019.03.010_bib91","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/imj.12661","article-title":"Comprehensive dietary education in treated gout patients does not further improve serum urate","volume":"45","author":"Holland","year":"2015","journal-title":"Intern Med J"},{"issue":"4","key":"10.1016\/j.berh.2019.03.010_bib92","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.amjmed.2013.12.019","article-title":"Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study","volume":"127","author":"Neogi","year":"2014","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.berh.2019.03.010_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2006.01.020","article-title":"Alcohol consumption as a trigger of recurrent gout attacks","volume":"119","author":"Zhang","year":"2006","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.berh.2019.03.010_bib94","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1136\/annrheumdis-2011-201215","article-title":"Purine-rich foods intake and recurrent gout attacks","volume":"71","author":"Zhang","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.03.010_bib95","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/1471-2474-14-278","article-title":"The effects of commercially available footwear on foot pain and disability in people with gout: a pilot study","volume":"14","author":"Rome","year":"2013","journal-title":"BMC Muscoskelet Disord"},{"issue":"1158","key":"10.1016\/j.berh.2019.03.010_bib96","first-page":"U109","article-title":"A\u00a0survey of indications, results and complications of surgery for tophaceous gout","volume":"115","author":"Kumar","year":"2002","journal-title":"N\u00a0Z Med J"},{"issue":"3","key":"10.1016\/j.berh.2019.03.010_bib97","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7547\/14-128","article-title":"Surgical management of gout in the foot and ankle a systematic review","volume":"106","author":"Poratt","year":"2016","journal-title":"J\u00a0Am Podiatr Med Assoc"},{"issue":"5","key":"10.1016\/j.berh.2019.03.010_bib98","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","article-title":"Medication adherence among patients with gout: a systematic review and meta-analysis","volume":"47","author":"Scheepers","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2019.03.010_bib99","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1742395310378761","article-title":"Patients and providers view gout differently: a qualitative study","volume":"6","author":"Harrold","year":"2010","journal-title":"Chronic Illness"},{"issue":"6","key":"10.1016\/j.berh.2019.03.010_bib100","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2019.03.010_bib101","first-page":"529","article-title":"Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study","volume":"56","author":"Abhishek","year":"2017","journal-title":"Rheumatology"},{"issue":"10156","key":"10.1016\/j.berh.2019.03.010_bib102","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.berh.2019.03.010_bib103","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003627","article-title":"Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study","volume":"4","author":"Goldfien","year":"2014","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.berh.2019.03.010_bib104","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/acr.23544","article-title":"Improved gout outcomes in primary care using a novel disease management program: a pilot study","volume":"70","author":"Bulbin","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.berh.2019.03.010_bib105","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3899\/jrheum.161062","article-title":"The pharmacodynamics, pharmacokinetics, and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout","volume":"44","author":"Steinberg","year":"2017","journal-title":"J\u00a0Rheumatol"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219300452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:18:42Z","timestamp":1761499122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694219300452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":105,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1521694219300452"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2019.03.010","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of complex gout in clinical practice: Update on therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2019.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}